Table 4.

Adverse events (n = 198)

Events, n (%)	Gefitinib (n = 106)	Erlotinib (n = 81)	Afatinib (n = 17)	Osimertinib (n = 93)
Any AE (≥ grade 3)	14 (13.2)	13 (16.0)	6 (35.3)	8 (8.6)
Cutaneous toxicity (rash, paronychia, and dry skin)	3 (2.8)	7 (8.6)	3 (16.7)	2 (2.2)
Diarrhea	1 (0.9)	1 (1.2)	2 (11.1)	0 (0.0)
Nausea	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Decreased appetite	1 (0.9)	2 (2.5)	2 (11.1)	2 (2.2)
AST/ALT elevation	6 (5.7)	0 (0.0)	0 (0.0)	0 (0.0)
Interstitial lung disease	3 (2.8)	2 (2.5)	0 (0.0)	4 (4.3)
Thromboembolism	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Any AE leading to discontinuation	16 (15.1)	14 (17.3)	8 (47.1)	12 (12.9)
Cutaneous toxicity (rash, paronychia, and dry skin)	2 (1.9)	9 (11.1)	2 (11.1)	1 (1.1)
Diarrhea	2 (1.9)	2 (2.5)	4 (22.2)	2 (2.2)
Nausea	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Decreased appetite	3 (2.8)	2 (2.5)	3 (16.7)	2 (2.2)
AST/ALT elevation	10 (9.4)	0 (0.0)	0 (0.0)	1 (1.1)
Interstitial lung disease	4 (3.8)	2 (2.5)	0 (0.0)	6 (6.5)
Thromboembolism	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Any AE leading to death	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
Interstitial lung disease	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)

AE, adverse event; AST, aspartate aminotransferase; ALT, alanine aminotransferase